TrialJournal of hematology & oncology2015

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status.

Wenzhao Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.